Spyros Papapetropoulos - 06 Jan 2022 Form 3 Insider Report for Vigil Neuroscience, Inc. (VIGL)

Role
Chief Medical Officer
Signature
/s/ Jennifer Ziolkowski, Attorney-in-Fact
Issuer symbol
VIGL
Transactions as of
06 Jan 2022
Net transactions value
$0
Form type
3
Filing time
06 Jan 2022, 19:31:50 UTC
Previous filing
24 Nov 2021
Next filing
03 Mar 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding VIGL Stock Option Grant (Right to Buy) 06 Jan 2022 Common Stock 149,904 $1.89 Direct F1
holding VIGL Stock Option Grant (Right to Buy) 06 Jan 2022 Common Stock 62,459 $3.78 Direct F2
holding VIGL Stock Option Grant (Right to Buy) 06 Jan 2022 Common Stock 59,006 $6.02 Direct F3
holding VIGL Stock Option Grant (Right to Buy) 06 Jan 2022 Common Stock 21,635 $9.57 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to this option vested and became exercisable on September 14, 2021, with the remainder vesting in 36 equal monthly installments thereafter.
F2 25% of the shares subject to this option shall vest and become exercisable on June 1, 2022, with the remainder vesting in 36 equal monthly installments thereafter.
F3 The shares subject to this option vest and become exercisable in 48 equal monthly installments, with the first installment vested September 13, 2021.
F4 The shares subject to this option vest and become exercisable in 48 equal monthly installments, with the first installment vested November 14, 2021.

Remarks:

Exhibit 24 - Power of Attorney